Biomarkers for placenta accreta spectrum (PAS) disorders
AssigneeBeth Israel Deaconess Medical Center, Inc.
InventorsScott Shainker, Towia Libermann, S. Ananth Karumanchi
Life of this patent
Estimating the term…
Abstract
Methods and compositions for detecting or determining a subject's risk of developing placenta accreta spectrum (PAS) are provided. Biomarkers are described that can be useful in detecting PAS in the second or third trimester of pregnancy.
Claims4
A method for characterizing placenta accreta spectrum biomarkers in a biological sample, the method comprising contacting a biological sample of the subject with a panel comprising four distinct capture molecules bound to a substrate, each of which specifically binds one of the following polypeptide or polynucleotide biomarkers:
- antithrombin III, plasminogen activator inhibitor 1, soluble Tie2, and soluble VEGF receptor 2, wherein the biological sample is a maternal plasma sample.
A method for characterizing placenta accreta spectrum in a pregnant subject, the method comprising characterizing placenta accreta spectrum biomarkers in a biological sample of a pregnant subject using a panel comprising three distinct capture molecules bound to a substrate, each of which specifically binds one of the following biomarkers:
- antithrombin III, soluble Tie2, and soluble VEGF receptor 2;
- wherein the biological sample is a maternal plasma sample;
- and
- wherein the method comprises contacting the biological sample with the panel.
Dependencies are inferred from the claim text.